Vimarsana
Biggest News Aggregation in the World

Page 43 - Knowledge Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Knowledge Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Knowledge Network Today - Breaking & Trending Today

Yeti Farm Creative Expands Sweet Tweets - Vimarsana News

Yeti Farm Creative Expands Sweet Tweets

Yeti Farm Creative is set to premiere a longer-form version of its Sweet Tweets digital series on Knowledge Kids and has named Zodiak Kids worldwide distributor.

Two centuries of B.C. history told through a diverse lens in new documentary series - Vimarsana News

Two centuries of B.C. history told through a diverse lens in new documentary series

A new four-part documentary tells the story of how British Columbia came to be, through a more inclusive lens, with voices of people from communities that have often been marginalized.

Source: cbc.ca
Realscreen » Archive » Extra: DCD Rights pre-sales; Passion acquires two new crime series - Vimarsana News

Realscreen » Archive » Extra: DCD Rights pre-sales; Passion acquires two new crime series

DCD Rights sales ahead of MIPCOM UK-based distributor DCD Rights has pre-sold a pair of new factual series to a range of broadcasters in the run-up to MIPCOM. The new history/travel series ...

NHPBS TV Schedule - Vimarsana News

NHPBS TV Schedule

TV Schedule for New Hampshire's only statewide locally owned and operated television network, engages minds, connects communities, and celebrates New Hampshire with Shows that entertain, educate and enrich.

Source: nhpbs.org
HUTCHMED's Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency - Vimarsana News

HUTCHMED's Marketing Authorization Application for Surufatinib Submitted and Validated by the European Medicines Agency

Share: – EMA commences review of surufatinib for the treatment of advanced neuroendocrine tumors – – Expands potential global reach of surufatinib, in addition to China where it is already launched, and in the U.S. where it is under review for marketing approval – HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) today announces that the European Medicines Agency ("EMA") has validated and accepted its marketing authorization application ("MAA") for surufatinib for the treatment of ...